BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
BCI
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, July 1, 2026
Breaking News: Science fiction realized: BCI tech is here
See today's BioWorld Science
Home
» Novel GPR52 agonist shows antipsychotic-like effects
To read the full story,
subscribe
or
sign in
.
Neurology/psychiatric
Novel GPR52 agonist shows antipsychotic-like effects
June 30, 2026
No Comments
Predominantly expressed in the striatum, a brain region involved in cognition, motivation and motor control, G protein-coupled receptor 52 (GPR52) regulates dopaminergic and glutamatergic signaling pathways implicated in psychiatric disorders.
BioWorld Science
New compound
Neurology/psychiatric